Targets of anti-hyperlipidemia drugs.
10.3969/j.issn.1672-7347.2013.01.019
- Author:
Hui LI
1
,
2
;
Xian JING
;
Xiaolan DENG
;
Dongsheng OUYANG
Author Information
1. Institute of Clinical Pharmacology, Central South University
2. Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China.
- Publication Type:Journal Article
- MeSH:
Binding Sites;
Humans;
Hyperlipidemias;
drug therapy;
Hypolipidemic Agents;
pharmacology;
therapeutic use;
Lipid Metabolism;
drug effects;
Receptors, Cytoplasmic and Nuclear;
drug effects
- From:
Journal of Central South University(Medical Sciences)
2013;38(1):101-108
- CountryChina
- Language:Chinese
-
Abstract:
Hyperlipidemia is one of the most important risk factors for atherosclerosis, coronary heart disease and other cardiovascular diseases. It is the main effect of lipid-lowering drugs to reduce the plasma low-density lipoprotein or to enhance high-density lipoprotein. Niemann-Pick C1 like 1 protein (NPC1L1), acyl-coenzyme A: cholesterol acyltransferases (ACAT), ATP binding cassette transporter G member 5 and member 8 (ABCG5/G8), microsomal triglyceride transfer protein (MTP), monoacylglycerol acyltransferase, diacylglycerol acyltransferases (MAGT), peroxisome proliferator-activated receptor (PPAR), farnesoid X receptor (FXR), and proprotein convertase subtilisin/kexin type 9 (PCSK9) play key roles in the metabolism of lipid, which are regarded as the targets of anti-hyperlipidemia drugs and evidence for clinic choice of lipid-lowering drugs. These proteins are considered as breakthrough points for new lipid-lowering drug development.
